Navigation Links
Phase 1 Studies Show Promise of QuatRx's Novel Compound, Sobetirome, for Lowering LDL Cholesterol Levels
Date:1/29/2008

Results from two separate Phase 1 studies show sobetirome, a selective

thyroid hormone receptor beta agonist, reduced levels of low-density

lipoprotein versus placebo

ANN ARBOR, Mich., Jan. 29 /PRNewswire/ -- QuatRx Pharmaceuticals, a privately-held biopharmaceutical company developing compounds for the treatment of major endocrine, metabolic and cardiovascular diseases, today announced results from two Phase 1 clinical studies with its novel lipid lowering compound, sobetirome (formerly QRX-431), in development for the treatment of elevated LDL cholesterol (also known as "bad cholesterol") levels. The results of the studies indicated LDL lowering with both single and multiple doses of sobetirome in a healthy volunteer population not enriched for elevated LDL levels. Sobetirome was generally well tolerated in both studies. Sobetirome is a new selective thyroid hormone receptor beta agonist that may activate reverse cholesterol transport.

"We are excited and extremely encouraged by these Phase 1 results indicating that sobetirome was generally well tolerated and showed lowering of LDL levels. We look forward to replicating these results in larger Phase 2 and 3 trials. We believe this new compound has potential as monotherapy or in combination with statins for the many patients who are unable to tolerate current therapies or who fail to achieve lipid treatment goals with statins alone," said Robert L. Zerbe, M.D., chief executive officer and president of QuatRx.

Study Results

Lipid-lowering effects in both single and multiple doses were seen in the randomized, double-blind, placebo-controlled Phase 1 studies of sobetirome. In the single dose study of 32 subjects, low-density lipoprotein (LDL) cholesterol levels decreased by up to 22% in subjects receiving up to 450 micrograms of sobetirome, compared to 2% in subjects who received placebo. The greatest reductions were observed 72 hours after dosing. In
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Surface Logix Achieves Objectives With SLx-4090 in Phase 2a Clinical Trial
2. Viventia Biotech to Explore Strategic Alternatives - Reports Positive Pivotal Phase III Interim Efficacy Data
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
5. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
6. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
7. Transgenes Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer
8. Amarin to Commence Phase II Trial With AMR101 in Age Associated Memory Impairment
9. Burrill Merchant Banking Advises NPS on Phase III Licensing Agreement
10. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
11. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... A new clinical study presented to the Amer...three-dimensional (3-D) automated ultrasound folli... an in vitro fertilization (IVF) cycle is effectiv...rement of the follicles. , ...ced Fertility Center of Chicago has just completed...
(Date:11/30/2009)...BUS, Ohio, Nov. 30 The Ohio Capita...e nation,s first minority business early-stage cap...December 3, is called "Transforming the Landscape ...Stage Capital Summit." It will feature several spe...ess leaders and local minority entrepreneurs. ,...
(Date:11/30/2009)...ILLE, Md., Nov. 30 Novav... company, announced today that the company will be...nce 2009 on December 2, 2009 at 12:30 pm local tim...provide an overview of the company,s business stra...ng milestones. A link to the live audio only pres...
(Date:11/30/2009)...ILLE, Md., Nov. 30 Novav...ompleted enrollment in the Phase II clinical study...commended strains) VLP vaccine candidate in health... This randomized, double-blind, active-controlled ...munogenicity of two different doses (15 mcg and 60...
Breaking Biology Technology:Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 2Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 3Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2NOVAVAX to Present at the Piper Jaffray 21st Annual Health Care Conference 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4
...al, Inc., the global leader in devices for clot re... that it has completed a $15 million round of fina...al firm New Enterprise Associates, Inc. (NEA) and ...s. , , "The positive developments at Concentric o...o participate in this round of financing very attr...
...sdaq: FOLD ) today announced the election of Sol...Barer currently serves as Chairman and Chief Execu...ry veteran, Dr. Barer brings over 20 years of mana...d respected leader who has helped transform Celgen...ical companies. , , John F. Crowley, President an...
...erence on Health Informatics (HEALTHINF 2009) will..."Open Source in European Health Care: The Tim...Portugal (PRWEB) January 8, 2009 -- OpenClinica wi...ing International Conference on Health Informatics...rtugal. The workshop, titled "Open Source in ...
Other Biology Technology:Concentric Medical Closes on $15 Million Financing 2Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2OpenClinica to Present at International Conference on Health Informatics, January 14-17, Porto, Portugal 2
(Date:12/1/2009)... been awarded a U.S. Air Force Center of Excellenc...nd adaptive materials, and to develop tools to opt...arfighter. , The $10.5 million Center, known as...ures and Improved Cognition (BIONIC) center, is be...professors in Georgia Tech,s School of Materials S...
(Date:12/1/2009)... -- iQor, a global provider of business process ou... InfoWorld 100 Awards Top 100 IT project of 2009... was the first submission for iQor. ,, "We are ...st of companies," said Vikas Kapoor, president and...e way we do business, allowing us to work faster, ...
(Date:12/1/2009)...he radio anymore. They,re used in everything from ...rolina State University is revolutionizing the fie...nnas that open the door to a host of new uses in f...yment. , Modern antennas are made from copper or...r they can be bent and how often before they bre...
Breaking Biology News(10 mins):Air Force Center of Excellence awarded in nanostructures and improved cognition 2Air Force Center of Excellence awarded in nanostructures and improved cognition 3Air Force Center of Excellence awarded in nanostructures and improved cognition 4iQor Named to InfoWorld 100 List of Top IT Projects of 2009 2Shape shifters: Researchers create new breed of antennas 2Travel Nurse Across America Expands Into New Offices 51338 1Travel Nurse Across America Expands Into New Offices 51338 2Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug 9 51336 1Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug 9 51336 2Moores UCSD Cancer Center Luau and Longboard Invitational Hosts Survivor Beach Aug 9 51336 3New research to reduce drug side effects 51334 1New research to reduce drug side effects 51334 2
...harmaceutical Research & Development (J&JP...w molecular mechanism that may underlie neuropathi...e of chronic neuropathic pain, and the preclinical...apies shown in this research, together present an ...at the severe pain associated with such common con...
... strains of influenza showed genetic differences f...d-virus flu shot was found to be effective in prev...uated-virus nasal spray vaccine also prevented ill...e determined by laboratory confirmation of flu inf...Earlier studies had suggested that the nasal spray...
...lege of Medicine of Yeshiva University have receiv...titute to study tumor "microenvironments" --where ...d chemicals in ways that all too often encourage c...he process known as metastasis. , With the new NC...nd structural biology at Einstein and the principa...
Other Biology News: New mechanism underlying pain found 2Flu shot effective against drifted influenza, nasal spray vaccine less so 2Flu shot effective against drifted influenza, nasal spray vaccine less so 3World's smallest cancer detection device 2
...n Ribonuclease Inhibitors have broad spectrum RNas...of eukaryotic RNases of the neutral type (1). The ...ovalently binding to RNases in a 1:1 ratio. The Ki...bitor to RNase (e.g., RNase A) is approximately 10...
HEPA Filtered Single Chamber Water Jacketed Incubator, CO2/O2 IR, 115V, 50/60 Hz from Thermo Scientific
CnAOSMC (Cn354-05) from European Collection of Cell Cultures (ECACC)
...d cell lines in combination with the corresponding...rameters. Nucleofector Kits are only functional in...rent cell lines can be transfected with this kit. ... given in brackets in percent (Efficiency [%] / vi...
Biology Products: